Pfizer, AstraZeneca Covid jabs highly effective against Delta variant

Two doses of Pfizer and AstraZeneca's Covid-19 vaccines are highly effective against hospitalisation from the Delta (B16172) variant, according to new analysis from Public Health England (PHE).

The analysis suggests that the Pfizer-BioNTech vaccine is 96 per cent effective against hospitalisation after two doses, while the Oxford-AstraZeneca vaccine is 92 per cent effective against hospitalisation after two doses.

These are comparable with vaccine effectiveness against hospitalisation from the Alpha (B117) variant: 96 per cent after two doses with Pfizer vaccine and 92 per cent after two doses from AstraZeneca vaccines.

The new analysis included 14,019 cases of the Delta variant, 166 of whom were hospitalised between 12 April and 4 June, looking at emergency hospital admissions in England. The results have been posted as a preprint. Preprints are yet to be peer-reviewed.

"This evidence of the effectiveness of two doses against variants shows just how crucial it is to get your second jab. If you have had your first dose but haven't booked your second yet -- please do so. It will help save lives and boost us on the road to recovery," said Health and Social Care Secretary Matt Hancock, in a statement.

"These hugely important findings confirm that the vaccines offer significant protection against hospitalisation from the Delta variant. The vaccines are the most important tool we have against Covid-19. Thousands of lives have already been saved because of them. It is absolutely vital to get both doses as soon as they are offered to you, to gain maximum protection against all existing and emerging variants," added Dr Mary Ramsay, Head of Immunisation at PHE.

A study by PHE in May showed that three weeks after the first dose of both Pfizer and AstraZeneca's coronavirus vaccine provided only 33 per cent protection against the Delta variant, while it offered 50 per cent effectiveness against the Alpha variant.

The B16172 variant was first discovered in India and is one of three related strains. It was declared as a variant of global concern last month by the World Health Organization (WHO). It is 60 per cent more transmissible than the Alpha strain identified in the UK.
 

 

‘Astra’s antibody fails to prevent Covid symptoms’
 
AstraZeneca Plc’s antibody cocktail was only 33 per cent effective at preventing Covid-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker.
 
The trial of 1,121 adult volunteers looked at whether the long-acting antibody combination could protect people who had recently been in contact with the SARS-CoV-2 virus in places like care homes.
 
The company said it’s running other studies that could help clarify the findings.  The study, conducted in the US and UK, showed 23 volunteers who got the AZD7442 cocktail developed symptomatic Covid following exposure to the disease, compared with 17 cases in the placebo group. Bloomberg
 
US Covid-19 pandemic fatalities cross painful 600,000 milestone
 
The United States on Monday crossed the grim milestone of 600,000 Covid-19 deaths, according to a Reuters tally, as slowing vaccination rates threaten the Biden administration target of having 70 per cent of US adults receive at least one shot and 160 million fully inoculated by July 4. The early success of the US vaccine rollout has had a huge impact on the pace of Covid-19 fatalities in the country.
 
It took 113 days to go from 500,000 total US Covid-19 deaths to 600,000 — the second slowest 100,000-death jump since the pandemic began. The nation went from 400,000 to 500,000 deaths in just 35 days. Reuters